HC Wainwright Has Lowered Expectations for Structure Therapeutics (NASDAQ:GPCR) Stock Price

Structure Therapeutics (NASDAQ:GPCR - Free Report) had its price target cut by HC Wainwright from $80.00 to $75.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Structure Therapeutics' FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at ($2.19) EPS.

Several other equities research analysts have also commented on the stock. Citigroup started coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target for the company. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $78.00.

Structure Therapeutics Price Performance

NASDAQ GPCR traded up $0.74 on Monday, hitting $25.17. The company had a trading volume of 826,116 shares, compared to its average volume of 932,879. The company has a market capitalization of $1.44 billion, a PE ratio of -34.01 and a beta of -1.69. The company's fifty day moving average price is $21.19 and its 200-day moving average price is $26.55. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, sell-side analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its position in shares of Structure Therapeutics by 5.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock valued at $112,816,000 after buying an additional 203,010 shares during the last quarter. Deep Track Capital LP raised its position in shares of Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after buying an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Structure Therapeutics by 3.7% in the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after buying an additional 63,990 shares during the last quarter. Capital International Investors raised its position in shares of Structure Therapeutics by 6.8% in the fourth quarter. Capital International Investors now owns 1,619,081 shares of the company's stock valued at $43,909,000 after buying an additional 103,059 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Structure Therapeutics by 29.4% in the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after buying an additional 322,601 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.